Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ChemoCentryx, Inc. - Common Stock (NQ: CCXI )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ChemoCentryx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Recap: ChemoCentryx Q4 Earnings
ChemoCentryx (NASDAQ:CCXI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Earnings Preview: ChemoCentryx
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Is Now The Time To Buy Stock In ChemoCentryx, Ideanomics Or Snowflake?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b... 
Via Benzinga
Why ChemoCentryx Shares Are Rising
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher a... 
Via Benzinga
ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis
The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of... 
Via Benzinga
Expert Ratings For ChemoCentryx
Analysts have provided the following ratings for ChemoCentryx (NASDAQ:CCXI... 
Via Benzinga
ChemoCentryx, inc (CCXI) Q3 2021 Earnings Call Transcript
CCXI earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Is It Too Late to Buy ChemoCentryx Stock?
The stock surged after obtaining FDA approval for avacopan. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
2 Super-Charged Growth Stocks to Buy Now
These two small drugmakers are poised for a long-winded growth spurt. 
Via The Motley Fool
45 Biggest Movers From Yesterday
Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on... 
Via Benzinga
BZ Chart Of The Day: ChemoCentryx
There’s an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCent... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021
Upgrades According to Vertical Research, the prior rating for C.H. Robinson Worldwide Inc (NASDAQ: 
Via Benzinga
Thinking About Buying Stock In Starbucks, Peloton Or ChemoCentryx?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in... 
Via Benzinga
Futures Slide As Soaring Oil Nears $85
While cash bonds may be closed, one can easily extrapolate where they would be trading based on TSY futures which are currently trading at a 1.65% equivalent. 
Via Talk Markets
Topics Bonds
Exposures Debt Markets
10 Biggest Price Target Changes For Monday
Keybanc lifted Netflix, Inc. (NASDAQ: NFLX) price target from $645 to $670. Netflix shares rose 0.1% to $633.00 in pre-market trading. JMP Securities raised ServiceNow, Inc. (... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down; Crude Oil Jumps 2%
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Nasdaq dropped around 75 points in the previous session. Futures for the Dow Jones Industrial... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Biggest Movers From Friday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
Exposures Product Safety
5 Stocks To Watch For October 11, 2021
Some of the stocks that may grab investor focus today are: Mandiant Inc (NASDAQ: MNDT) reported the completion of divestiture of its FireEye Products unit to McAfee Enterprise... 
Via Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
Why ChemoCentryx Stock Skyrocketed Today
Investors are excited about the biotech's game-changing new drug. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.24% to 34,835.06 while the NASDAQ fell 0.13% to 14,635.04. The S&P also rose, gaining 0.13% to 4,405.69. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
The broader market was mixed on Friday. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.